English

Enlivex Therapeutics Ltd.

EDGAR

ENLV Report (type unavailable) · filed 2026-09-29

302 filing records in this dataset, filed from 2014-02-07 to 2026-09-29. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 5.52 million uref_1808839461 2026-06-30 Source
Exact value

5518000 uref_1808839461
Long-term debt including current maturities: 7.16 million USD 2023-06-30 Source
Exact value

7159000 USD
Shares outstanding: 16.8 million uref_753409712 2026-06-30 Source
Exact value

16832017 uref_753409712

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-29.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 1.25 billion

Prior period

−USD 15.01 million

2024-01-01 – 2024-12-31
Current period

USD 1.24 billion

2025-01-01 – 2025-12-31

Exact inputs and evidence

1235528000 − -15014000 = 1250542000 USD

-15014000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1235528000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Enlivex Therapeutics Ltd. · 2025-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Year-over-year change in Net income: 1250542000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 1235528000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1356427 Filing: 000121390026033857 Input fundies:NetIncome: -15014000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1356778 Filing: 000121390026033857
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.59 million

Prior period

−USD 13.01 million

2024-01-01 – 2024-12-31
Current period

−USD 10.42 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-10416000 − -13008000 = 2592000 USD

-13008000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-10416000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Enlivex Therapeutics Ltd. · 2025-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Year-over-year change in Operating cash flow: 2592000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -10416000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1375336 Filing: 000121390026033857 Input fundies:OperatingCashFlow: -13008000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1375792 Filing: 000121390026033857
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-34%

Prior period

USD 103,000

2024-01-01 – 2024-12-31
Current period

USD 68,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

68000 − 103000 = -35000 USD

103000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
68000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Enlivex Therapeutics Ltd. · 2025-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Year-over-year change in Capital expenditure: -35000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 68000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1377953 Filing: 000121390026033857 Input fundies:CapitalExpenditure: 103000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1378275 Filing: 000121390026033857
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 16.02 million Exact value Exact value: -16022000 USD 2016-01-01 – 2016-12-31: -16022000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2016-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -16022000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16022000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020001652/enlv-20181231.xml#38635 Filing: 000121390020001652 The citation records this snapshot. The page link may show a newer release later.	−USD 15.49 million Exact value Exact value: -15486000 USD 2016-01-01 – 2016-12-31: -15486000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2016-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -15486000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15486000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020001652/enlv-20181231.xml#317072 Filing: 000121390020001652 The citation records this snapshot. The page link may show a newer release later.	USD 18,000 Exact value Exact value: 18000 USD 2016-01-01 – 2016-12-31: 18000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2016-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 18000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020001652/enlv-20181231.xml#318541 Filing: 000121390020001652 The citation records this snapshot. The page link may show a newer release later.	−USD 15.5 million Calculation and evidence -15486000 − 18000 USD Exact free cash flow: -15504000 USD 2016-01-01 – 2016-12-31: -15486000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 18000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2016-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -15504000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15486000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020001652/enlv-20181231.xml#317072 Filing: 000121390020001652 Input fundies:CapitalExpenditure: 18000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020001652/enlv-20181231.xml#318541 Filing: 000121390020001652 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 2.5 million Exact value Exact value: -2504000 USD 2017-01-01 – 2017-12-31: -2504000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2017-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -2504000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2504000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/enlv-20191231.xml#597360 Filing: 000121390020010632 The citation records this snapshot. The page link may show a newer release later.	−USD 2.3 million Exact value Exact value: -2304000 USD 2017-01-01 – 2017-12-31: -2304000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2017-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -2304000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2304000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/enlv-20191231.xml#589548 Filing: 000121390020010632 The citation records this snapshot. The page link may show a newer release later.	USD 130,000 Exact value Exact value: 130000 USD 2017-01-01 – 2017-12-31: 130000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2017-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 130000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 130000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/enlv-20191231.xml#601028 Filing: 000121390020010632 The citation records this snapshot. The page link may show a newer release later.	−USD 2.43 million Calculation and evidence -2304000 − 130000 USD Exact free cash flow: -2434000 USD 2017-01-01 – 2017-12-31: -2304000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 130000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2017-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -2434000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2304000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/enlv-20191231.xml#589548 Filing: 000121390020010632 Input fundies:CapitalExpenditure: 130000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/enlv-20191231.xml#601028 Filing: 000121390020010632 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 4.24 million Exact value Exact value: -4242000 USD 2018-01-01 – 2018-12-31: -4242000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2018-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -4242000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4242000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390021023865/f20f2020_enlivexthera.htm#1570791 Filing: 000121390021023865 The citation records this snapshot. The page link may show a newer release later.	−USD 3.16 million Exact value Exact value: -3161000 USD 2018-01-01 – 2018-12-31: -3161000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2018-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -3161000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3161000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390021023865/f20f2020_enlivexthera.htm#1584702 Filing: 000121390021023865 The citation records this snapshot. The page link may show a newer release later.	USD 461,000 Exact value Exact value: 461000 USD 2018-01-01 – 2018-12-31: 461000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2018-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 461000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 461000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390021023865/f20f2020_enlivexthera.htm#1587015 Filing: 000121390021023865 The citation records this snapshot. The page link may show a newer release later.	−USD 3.62 million Calculation and evidence -3161000 − 461000 USD Exact free cash flow: -3622000 USD 2018-01-01 – 2018-12-31: -3161000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 461000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2018-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -3622000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3161000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390021023865/f20f2020_enlivexthera.htm#1584702 Filing: 000121390021023865 Input fundies:CapitalExpenditure: 461000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390021023865/f20f2020_enlivexthera.htm#1587015 Filing: 000121390021023865 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 9.38 million Exact value Exact value: -9384000 USD 2019-01-01 – 2019-12-31: -9384000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2019-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -9384000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9384000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390022022527/f20f2021_enlivexthera.htm#1275778 Filing: 000121390022022527 The citation records this snapshot. The page link may show a newer release later.	−USD 7.04 million Exact value Exact value: -7041000 USD 2019-01-01 – 2019-12-31: -7041000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2019-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -7041000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7041000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390022022527/f20f2021_enlivexthera.htm#1290077 Filing: 000121390022022527 The citation records this snapshot. The page link may show a newer release later.	USD 193,000 Exact value Exact value: 193000 USD 2019-01-01 – 2019-12-31: 193000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2019-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 193000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 193000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390022022527/f20f2021_enlivexthera.htm#1292275 Filing: 000121390022022527 The citation records this snapshot. The page link may show a newer release later.	−USD 7.23 million Calculation and evidence -7041000 − 193000 USD Exact free cash flow: -7234000 USD 2019-01-01 – 2019-12-31: -7041000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 193000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2019-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -7234000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7041000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390022022527/f20f2021_enlivexthera.htm#1290077 Filing: 000121390022022527 Input fundies:CapitalExpenditure: 193000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390022022527/f20f2021_enlivexthera.htm#1292275 Filing: 000121390022022527 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 11.82 million Exact value Exact value: -11824000 USD 2020-01-01 – 2020-12-31: -11824000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2020-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -11824000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11824000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390023028398/f20f2022_enlivextherap.htm#1304558 Filing: 000121390023028398 The citation records this snapshot. The page link may show a newer release later.	−USD 11.01 million Exact value Exact value: -11007000 USD 2020-01-01 – 2020-12-31: -11007000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2020-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -11007000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11007000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390023028398/f20f2022_enlivextherap.htm#1316584 Filing: 000121390023028398 The citation records this snapshot. The page link may show a newer release later.	USD 1.02 million Exact value Exact value: 1019000 USD 2020-01-01 – 2020-12-31: 1019000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2020-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 1019000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1019000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390023028398/f20f2022_enlivextherap.htm#1318749 Filing: 000121390023028398 The citation records this snapshot. The page link may show a newer release later.	−USD 12.03 million Calculation and evidence -11007000 − 1019000 USD Exact free cash flow: -12026000 USD 2020-01-01 – 2020-12-31: -11007000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1019000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2020-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -12026000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11007000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390023028398/f20f2022_enlivextherap.htm#1316584 Filing: 000121390023028398 Input fundies:CapitalExpenditure: 1019000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390023028398/f20f2022_enlivextherap.htm#1318749 Filing: 000121390023028398 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 14.47 million Exact value Exact value: -14468000 USD 2021-01-01 – 2021-12-31: -14468000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2021-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -14468000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14468000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390024037878/ea0204570-20f_enlivex.htm#1467030 Filing: 000121390024037878 The citation records this snapshot. The page link may show a newer release later.	−USD 17.54 million Exact value Exact value: -17542000 USD 2021-01-01 – 2021-12-31: -17542000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2021-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -17542000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17542000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390024037878/ea0204570-20f_enlivex.htm#1482319 Filing: 000121390024037878 The citation records this snapshot. The page link may show a newer release later.	USD 1.63 million Exact value Exact value: 1625000 USD 2021-01-01 – 2021-12-31: 1625000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2021-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 1625000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1625000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390024037878/ea0204570-20f_enlivex.htm#1484561 Filing: 000121390024037878 The citation records this snapshot. The page link may show a newer release later.	−USD 19.17 million Calculation and evidence -17542000 − 1625000 USD Exact free cash flow: -19167000 USD 2021-01-01 – 2021-12-31: -17542000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1625000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2021-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -19167000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17542000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390024037878/ea0204570-20f_enlivex.htm#1482319 Filing: 000121390024037878 Input fundies:CapitalExpenditure: 1625000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390024037878/ea0204570-20f_enlivex.htm#1484561 Filing: 000121390024037878 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 31.06 million Exact value Exact value: -31060000 USD 2022-01-01 – 2022-12-31: -31060000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2022-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -31060000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31060000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm#1179357 Filing: 000121390025037657 The citation records this snapshot. The page link may show a newer release later.	−USD 23.95 million Exact value Exact value: -23953000 USD 2022-01-01 – 2022-12-31: -23953000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2022-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -23953000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23953000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm#1195128 Filing: 000121390025037657 The citation records this snapshot. The page link may show a newer release later.	USD 8.12 million Exact value Exact value: 8122000 USD 2022-01-01 – 2022-12-31: 8122000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2022-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 8122000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8122000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm#1197368 Filing: 000121390025037657 The citation records this snapshot. The page link may show a newer release later.	−USD 32.08 million Calculation and evidence -23953000 − 8122000 USD Exact free cash flow: -32075000 USD 2022-01-01 – 2022-12-31: -23953000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 8122000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2022-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -32075000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23953000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm#1195128 Filing: 000121390025037657 Input fundies:CapitalExpenditure: 8122000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm#1197368 Filing: 000121390025037657 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 29.07 million Exact value Exact value: -29068000 USD 2023-01-01 – 2023-12-31: -29068000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2023-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -29068000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29068000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1357130 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	−USD 23.52 million Exact value Exact value: -23523000 USD 2023-01-01 – 2023-12-31: -23523000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2023-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -23523000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23523000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1376248 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	USD 236,000 Exact value Exact value: 236000 USD 2023-01-01 – 2023-12-31: 236000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2023-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 236000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 236000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1378598 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	−USD 23.76 million Calculation and evidence -23523000 − 236000 USD Exact free cash flow: -23759000 USD 2023-01-01 – 2023-12-31: -23523000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 236000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2023-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -23759000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23523000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1376248 Filing: 000121390026033857 Input fundies:CapitalExpenditure: 236000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1378598 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 15.01 million Exact value Exact value: -15014000 USD 2024-01-01 – 2024-12-31: -15014000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2024-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: -15014000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15014000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1356778 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	−USD 13.01 million Exact value Exact value: -13008000 USD 2024-01-01 – 2024-12-31: -13008000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2024-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -13008000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13008000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1375792 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	USD 103,000 Exact value Exact value: 103000 USD 2024-01-01 – 2024-12-31: 103000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2024-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 103000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 103000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1378275 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	−USD 13.11 million Calculation and evidence -13008000 − 103000 USD Exact free cash flow: -13111000 USD 2024-01-01 – 2024-12-31: -13008000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 103000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2024-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -13111000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13008000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1375792 Filing: 000121390026033857 Input fundies:CapitalExpenditure: 103000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1378275 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	USD 1.24 billion Exact value Exact value: 1235528000 USD 2025-01-01 – 2025-12-31: 1235528000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Enlivex Therapeutics Ltd. · 2025-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Net Income: 1235528000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1235528000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1356427 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	−USD 10.42 million Exact value Exact value: -10416000 USD 2025-01-01 – 2025-12-31: -10416000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Enlivex Therapeutics Ltd. · 2025-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Operating Cash Flow: -10416000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10416000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1375336 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	USD 68,000 Exact value Exact value: 68000 USD 2025-01-01 – 2025-12-31: 68000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Enlivex Therapeutics Ltd. · 2025-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Capital Expenditure: 68000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 68000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1377953 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.	−USD 10.48 million Calculation and evidence -10416000 − 68000 USD Exact free cash flow: -10484000 USD 2025-01-01 – 2025-12-31: -10416000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 68000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Enlivex Therapeutics Ltd. · 2025-12-31 Enlivex Therapeutics Ltd. (edgar:1596812) Free cash flow: -10484000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:22:51Z Snapshot: a3c5420bbaf616d3d1506af0c2d11fe9c67895193365b1c020675373de79fc70 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1596812?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10416000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1375336 Filing: 000121390026033857 Input fundies:CapitalExpenditure: 68000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1596812/000121390026033857/ea0282960-20f_enlivex.htm#1377953 Filing: 000121390026033857 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

302 filings · 1,049 latest values · 1,049 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001596812, 1596812, ENLV, ORPN, edgar:1596812

Also known as BIO BLAST PHARMA LTD., Bioblast Pharma Ltd., ENLIVEX LTD., ENLIVEX THERAPEUTICS LTD., Enlivex Ltd., Enlivex Therapeutics Ltd., Enlivex Therapeutics, Ltd.

Enlivex Therapeutics Ltd.

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation